89 Zr/ 177 Lu-Labeled Radioimmunoconjugates Targeting SORT1 for Cancer Theranostics
Journal of Medicinal Chemistry · 12.03.2026 · 69 (5) · 6254-6265
DOI: 10.1021/acs.jmedchem.6c00007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.03.2026. Verfasst von Jingyue Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Experimental Teratology of the Ministry of Education and Center for Experimental Nuclear Medicine, School of Basic Medical Science…. Hauptthemen laut MEDLINE: Zirconium, Radioisotopes, Lutetium, Immunoconjugates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China, New Cornerstone Science Foundation.
Abstract (Originalsprache)
Sortilin (SORT1), a receptor overexpressed across multiple malignancies, represents a promising but untapped target for radionuclide theranostics. We utilized the SORT1-targeted antibody latozinemab to develop [89Zr]Zr-DFO-latozinemab and [177Lu]Lu-DOTA-latozinemab, providing a proof-of-concept for SORT1-targeted theranostics. Transcriptional analyses confirmed significant SORT1 upregulation across multiple malignancies, notably in melanoma. Melanoma TMA confirmed high SORT1 expression (mean H-score 189.79). The conjugates maintained picomolar affinity and demonstrated high internalization. [89Zr]Zr-DFO-latozinemab PET imaging enabled specific and high-contrast tumor visualization, with uptake peaking at 72 h in HT-1080-SORT1 models (SUVmean = 5.8 ± 0.69). In SK-MEL-28 xenografts, [177Lu]Lu-DOTA-latozinemab showed high, long tumor accumulation (39.08 ± 13.23%ID/g at 72 h) and favorable tumor-to-blood ratios (11.51 ± 6.17 at 96 h). Moreover, 11.1 MBq [177Lu]Lu-DOTA-latozinemab significantly suppressed tumor growth via induction of DNA damage, as evidenced by increased 53BP1 foci. These findings establish the first SORT1-directed theranostic radiopharmaceutical pair, exhibiting high specificity and therapeutic potency for managing SORT1-positive cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Experimental Teratology of the Ministry of Education and Center for Experimental Nuclear Medicine, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 2…
- Changping Laboratory, Beijing 102206, China.
- Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education…
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department…
- Peking University-Tsinghua University Center for Life Sciences, Beijing 100871, China.
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
- New Cornerstone Science Foundation
- Changping Laboratory
Zitieren
APA
Gao, J., Cen, T., Chen, J., Li, X., Fan, X., Xu, M., Gao, F., & Liu, Z. (2026). 89 Zr/ 177 Lu-Labeled Radioimmunoconjugates Targeting SORT1 for Cancer Theranostics. Journal of Medicinal Chemistry, 69(5), 6254-6265. https://doi.org/10.1021/acs.jmedchem.6c00007
Vancouver
Gao J, Cen T, Chen J, Li X, Fan X, Xu M, et al. 89 Zr/ 177 Lu-Labeled Radioimmunoconjugates Targeting SORT1 for Cancer Theranostics. Journal of Medicinal Chemistry. 2026;69(5):6254-6265. doi:10.1021/acs.jmedchem.6c00007
BibTeX
@article{Gao2026,
author = {Gao, Jingyue and Cen, Tianyi and Chen, Junyi and Li, Xinwei and Fan, Xiaowei and Xu, Mengxin and Gao, Feng and Liu, Zhibo},
title = {89 Zr/ 177 Lu-Labeled Radioimmunoconjugates Targeting SORT1 for Cancer Theranostics},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {5},
pages = {6254--6265},
doi = {10.1021/acs.jmedchem.6c00007}
}
EUVIMED